Auransa Inc.

Sct II LLC

Sct Incorporated

Kevin J Kim

Joseph C Wu

Pek Yee Lum

Zhong Zhong

Sidney Paul Elmer

Eunhye Park

Viwat Visuthikraisee

Eithon Michael G Cadag

Christopher G Armstrong

Thomas Bernard Freeman

Lisa Maria Lucia Pham

Guanyi Huang

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4&#x2032;,5&#x2032;-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Growing community of inventors

Menlo Park, CA, United States of America

Kevin J Kim